Other uses of dexrazoxane: Savene, the first proven antidote against anthracycline extravasation injuries
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Other uses of dexrazoxane : Savene, the first proven antidote against anthracycline extravasation injuries. / Langer, Seppo W; Jensen, Peter Buhl; Sehested, Maxwell.
I: Cardiovascular Toxicology, Bind 7, Nr. 2, 2007, s. 151-3.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Other uses of dexrazoxane
T2 - Savene, the first proven antidote against anthracycline extravasation injuries
AU - Langer, Seppo W
AU - Jensen, Peter Buhl
AU - Sehested, Maxwell
PY - 2007
Y1 - 2007
N2 - Dexrazoxane has been in clinical use for more than 25 years for prevention of cardiotoxicity in anthracycline based anticancer therapy. However, we discovered another property of the compound, i.e. the ability to prevent the devastating tissue necrosis after accidental extravasation of anthracyclines. The preclinical and clinical studies leading to the clinical implementation of Savene (dexrazoxane) as the first and only proven antidote in anthracycline extravasation are described in short.
AB - Dexrazoxane has been in clinical use for more than 25 years for prevention of cardiotoxicity in anthracycline based anticancer therapy. However, we discovered another property of the compound, i.e. the ability to prevent the devastating tissue necrosis after accidental extravasation of anthracyclines. The preclinical and clinical studies leading to the clinical implementation of Savene (dexrazoxane) as the first and only proven antidote in anthracycline extravasation are described in short.
KW - Animals
KW - Anthracyclines/adverse effects
KW - Antibiotics, Antineoplastic/adverse effects
KW - Cardiovascular Agents/therapeutic use
KW - Clinical Trials as Topic
KW - Clinical Trials, Phase I as Topic
KW - Clinical Trials, Phase II as Topic
KW - Heart Diseases/chemically induced
KW - Humans
KW - Mice
KW - Razoxane/therapeutic use
U2 - 10.1007/s12012-007-0021-5
DO - 10.1007/s12012-007-0021-5
M3 - Review
C2 - 17652821
VL - 7
SP - 151
EP - 153
JO - Cardiovascular Toxicology
JF - Cardiovascular Toxicology
SN - 1530-7905
IS - 2
ER -
ID: 247891580